Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 13, 2018 4:05 PM ESTNASHVILLE, Tenn., Nov. 13, 2018 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration (FDA) approved brands. Net revenues for the quarter were $8.5 million. At the end of the third quarter, Cumberland had $87 million in total assets, including approximately $48 million in cash and marketable securities.
... More